In a carefully performed retrospective study of 1,314 patients undergoing cardiac surgery, Shahin and colleagues found that postoperative use of dobutamine was independently associated with a 2.3-fold increase in mortality and a 2.7-fold increased risk of renal dysfunction, after correcting for preoperative risk, cardiac function, intraoperative management and complications, and cardiac index [1] . A parallel greedy matching propensity analysis in 123 inotrope-exposed patients and 123 un exposed patients confi rmed these fi ndings [1] . Th is study builds upon that previously reported by Fellahi and colleagues in 657 cardiac surgical patients [2] .
Th e decision to start an inotrope after cardiac surgery is often based on physician whim [3] and there is a general nonappreciation of harm. For many years we have displayed a blind devotion to catecholamines, aware but accepting of the occasional problems of tachycardia, arrhythmia and dusky digits. Like furosemide, oxygen, aspirin, digoxin and other familiar friends, catecholamines and phosphodiesterase inhibitors became established before formal long-term outcomes testing of drugs became mandatory, so proof of benefi t and safety profi les were never properly characterised. Th e treatment provided what was claimed on the package insert (an inotropic action) and we looked no further.
Dobutamine was key to Shoemaker and colleagues' concept of supranormal circulatory optimisation of highrisk surgical patients [4] , and, to be fair, was an integral part of a successful optimisation protocol after cardiac surgery that targeted mixed venous oxygen saturation and lactate [5] . A perioperative goal-driven approach may thus be more effi cacious -and safer -than empiric administration, but this should not be freely extrapolated to other conditions. For example, the Shoemaker approach was forcefully marketed towards managing established severe sepsis and shock, yet, when formally challenged, its use proved deleterious in a dose-dependent manner [6] . While this deterred intensivists from using high doses to achieve targeted values of oxygen delivery and consumption, the general use of catecholamines remains unabated.
A further fi llip came from Rivers and colleagues' Early Goal-Directed Th erapy strategy for patients presenting with severe sepsis [7] ; this study led to dobutamine becom ing enshrined in the Surviving Sepsis Campaign guidelines [8] , albeit based on a mere 18 patients whose outcomes remain unknown. Recent studies in shocked patients showed equivalent mortality rates when ran domised to epinephrine or norepinephrine plus dobuta mine [9, 10] . But are these equally good or equally bad? A wealth of animal and cell studies show a wide range of covert harm from cate chol amines; for instance, stimu lation of bacterial growth yet concurrent immunosup pres sion, decreased metabolic effi ciency, potent thrombo genicity, tissue hypoxia through excessive microvascular vaso constriction, and myocardial damage [11] . A retrospective analysis of cate cholamine use in a septic shock trial revealed increased dose-related mortality with progressive increases in blood pressure [12] .
What options do we have? Currently, these options are relatively limited and further extensive study is required before any can be strongly endorsed. Phosphodiesterase inhibitors, like catecholamines, have similar detrimental outcomes, and this appears to be a class eff ect [13, 14] . Vasopressin or synthetic analogues such as terlipressin may be potentially superior vasopressors, while levosimendan off ers a viable alternative in low cardiac output states by increasing contractility through a variety of mechanisms including increased cardiomyocyte calcium sensitisation and peripheral vasodilatation, although not at the expense of a large increase in cardiac work.
New agents in development such as myosin activators and the Na + /K + -ATPase antagonists show promise, as does the concept of metabolic modulation -encouraging the mitochondria to use glucose preferentially over fatty acid, thereby generating ATP more effi ciently in terms of oxygen consumption [15] . Th is modulation can be achieved by blocking fatty acid entry into mitochondria (for example, using a carnitine palmitoyl transferase inhibitor such as per hexiline) or by enhancing utilisation of glucose through a high-dose glucose-insulin-potassium infusion. Th is strategy has become the treatment of choice for life-threatening overdoses of calcium channel blockers and some antidepressants. While an immediate, end-of-the-needle eff ect is not seen, the treatment still merits exploration in other critically ill patient groups.
In the short term, we can also focus on catecholamine sparing. What blood pressure should we aim for in an individual patient? Guidelines target populations not individuals. If perfusion appears adequate at a mean of, say, 55 to 60 mmHg, is there any point in driving it higher? Furthermore, does the patient need heavy sedation, a frequent side eff ect of which is hypotension? Th e crucial recognition of iatrogenic harm through blood transfusion, high tidal volumes, excess sedation, and so forth, can (and should) be readily extended to catecholamine use.
